New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kazuhiko Uchiyama, Tomohisa Takagi, Yasunori Iwamoto, Norihiko Kondo, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiro Katada, Osamu Handa, Takeshi Ishikawa, Hiroaki Yasuda, Junichi Sakagami, Hideyuki Konishi, Nobuaki Yagi, Yuji Naito, Yoshito Itoh
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
R
Q
Acceso en línea:https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bb1a37dcdfb54bc8bfafdf5d75194975
record_format dspace
spelling oai:doaj.org-article:bb1a37dcdfb54bc8bfafdf5d751949752021-11-18T08:21:37ZNew genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.1932-620310.1371/journal.pone.0095080https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d751949752014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24762746/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) inhibits TPMT activity, and that increased 6-thioguanine nucleotide (6-TGN, a metabolite of AZA) blood concentrations result in an increased number of ADRs. In this study, single nucleotide polymorphisms (SNPs) related to differential gene expression affecting AZA drug metabolism in combination therapy with 5-ASA were examined.<h4>Methods</h4>To identify genetic biomarkers for the prediction of 6-TGN blood concentration, ExpressGenotyping analysis was used. ExpressGenotyping analysis is able to detect critical pharmacogenetic SNPs by analyzing drug-induced expression allelic imbalance (EAI) of premature RNA in HapMap lymphocytes. We collected blood samples on 38 patients with inflammatory bowel disease treated with AZA and corroboration of the obtained SNPs was attempted in clinical samples.<h4>Results</h4>A large number of SNPs with AZA/5-ASA-induced EAI within the investigated HapMap lymphocytes was identified by ExpressGenotyping analysis. The respective SNPs were analyzed in IBD patients' blood samples. Among these SNPs, several that have not yet been described to be induced by AZA/5-ASA were found. SNPs within SLC38A9 showed a particular correlation with patients' 6-TGN blood concentrations.<h4>Conclusions</h4>Based on these results, ExpressGenotyping analysis and genotyping of patients appears to be a useful way to identify inter-individual differences in drug responses and ADRs to AZA/5-ASA. This study provides helpful information on genetic biomarkers for optimized AZA/5-ASA treatment of IBD patients.Kazuhiko UchiyamaTomohisa TakagiYasunori IwamotoNorihiko KondoTetsuya OkayamaNaohisa YoshidaKazuhiro KamadaKazuhiro KatadaOsamu HandaTakeshi IshikawaHiroaki YasudaJunichi SakagamiHideyuki KonishiNobuaki YagiYuji NaitoYoshito ItohPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 4, p e95080 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Kazuhiko Uchiyama
Tomohisa Takagi
Yasunori Iwamoto
Norihiko Kondo
Tetsuya Okayama
Naohisa Yoshida
Kazuhiro Kamada
Kazuhiro Katada
Osamu Handa
Takeshi Ishikawa
Hiroaki Yasuda
Junichi Sakagami
Hideyuki Konishi
Nobuaki Yagi
Yuji Naito
Yoshito Itoh
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
description <h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) inhibits TPMT activity, and that increased 6-thioguanine nucleotide (6-TGN, a metabolite of AZA) blood concentrations result in an increased number of ADRs. In this study, single nucleotide polymorphisms (SNPs) related to differential gene expression affecting AZA drug metabolism in combination therapy with 5-ASA were examined.<h4>Methods</h4>To identify genetic biomarkers for the prediction of 6-TGN blood concentration, ExpressGenotyping analysis was used. ExpressGenotyping analysis is able to detect critical pharmacogenetic SNPs by analyzing drug-induced expression allelic imbalance (EAI) of premature RNA in HapMap lymphocytes. We collected blood samples on 38 patients with inflammatory bowel disease treated with AZA and corroboration of the obtained SNPs was attempted in clinical samples.<h4>Results</h4>A large number of SNPs with AZA/5-ASA-induced EAI within the investigated HapMap lymphocytes was identified by ExpressGenotyping analysis. The respective SNPs were analyzed in IBD patients' blood samples. Among these SNPs, several that have not yet been described to be induced by AZA/5-ASA were found. SNPs within SLC38A9 showed a particular correlation with patients' 6-TGN blood concentrations.<h4>Conclusions</h4>Based on these results, ExpressGenotyping analysis and genotyping of patients appears to be a useful way to identify inter-individual differences in drug responses and ADRs to AZA/5-ASA. This study provides helpful information on genetic biomarkers for optimized AZA/5-ASA treatment of IBD patients.
format article
author Kazuhiko Uchiyama
Tomohisa Takagi
Yasunori Iwamoto
Norihiko Kondo
Tetsuya Okayama
Naohisa Yoshida
Kazuhiro Kamada
Kazuhiro Katada
Osamu Handa
Takeshi Ishikawa
Hiroaki Yasuda
Junichi Sakagami
Hideyuki Konishi
Nobuaki Yagi
Yuji Naito
Yoshito Itoh
author_facet Kazuhiko Uchiyama
Tomohisa Takagi
Yasunori Iwamoto
Norihiko Kondo
Tetsuya Okayama
Naohisa Yoshida
Kazuhiro Kamada
Kazuhiro Katada
Osamu Handa
Takeshi Ishikawa
Hiroaki Yasuda
Junichi Sakagami
Hideyuki Konishi
Nobuaki Yagi
Yuji Naito
Yoshito Itoh
author_sort Kazuhiko Uchiyama
title New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
title_short New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
title_full New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
title_fullStr New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
title_full_unstemmed New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
title_sort new genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
publisher Public Library of Science (PLoS)
publishDate 2014
url https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975
work_keys_str_mv AT kazuhikouchiyama newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT tomohisatakagi newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT yasunoriiwamoto newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT norihikokondo newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT tetsuyaokayama newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT naohisayoshida newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT kazuhirokamada newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT kazuhirokatada newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT osamuhanda newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT takeshiishikawa newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT hiroakiyasuda newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT junichisakagami newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT hideyukikonishi newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT nobuakiyagi newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT yujinaito newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
AT yoshitoitoh newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid
_version_ 1718421884991700992